Risk Indicators of Sarcoidosis Evolution-Unified Protocol
RISE-UP
Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis
2 other identifiers
observational
200
1 country
2
Brief Summary
The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 30, 2022
CompletedFirst Posted
Study publicly available on registry
October 5, 2022
CompletedStudy Start
First participant enrolled
January 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 30, 2030
January 8, 2026
January 1, 2026
7.2 years
September 30, 2022
January 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean Change in Forced Vital Capacity in Liters
Forced vital capacity (FVC) is the total amount of air in liters exhaled during a forced maneuver.
Baseline and 24 months
Eligibility Criteria
adults who meet criteria for the diagnosis of pulmonary sarcoidosis
You may qualify if:
- Adults with a diagnosis of sarcoidosis over the age of 18
You may not qualify if:
- Inability to tolerate study procedures as determined by the investigator
- Pregnant or breastfeeding
- Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
- Hematocrit (Packed Cell Volume) \< 25%
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, San Franciscolead
- Vanderbilt University Medical Centercollaborator
- Wayne State Universitycollaborator
- University of Texas, Southwestern Medical Center at Dallascollaborator
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
Study Sites (2)
University of Maryland
Baltimore, Maryland, 21201, United States
UT Southwestern
Dallas, Texas, 75390, United States
Related Publications (1)
Drake WP, Hsia C, Samavati L, Yu M, Cardenas J, Gianella FG, Boscardin J, Koth LL. Risk Indicators of Sarcoidosis Evolution-Unified Protocol (RISE-UP): protocol for a multi-centre, longitudinal, observational study to identify clinical features that are predictive of sarcoidosis progression. BMJ Open. 2023 Apr 3;13(4):e071607. doi: 10.1136/bmjopen-2023-071607.
PMID: 37012011DERIVED
Biospecimen
blood samples for serum isolation
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laura Koth
University of California, San Francisco
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 30, 2022
First Posted
October 5, 2022
Study Start
January 10, 2023
Primary Completion (Estimated)
March 30, 2030
Study Completion (Estimated)
March 30, 2030
Last Updated
January 8, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share